>>…most of your concerns listed here are true for all biotech companies and drugs.<<
True, but it’s a matter of degree. When you are talking about long-term treatment with a systemic drug for a small organ like the eye, the concern is greater.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”